Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Regeneron Pharmaceuticals, Inc. (REGN) had Revenue of $13.12B for the most recently reported fiscal year, ending 2023-12-31.

Quarterly Annual

Figures for fiscal year ending 2023-12-31

Income Statement Financials
Revenue	$13.12B
Net Income	$3.95B
Cost of Goods Sold	$1.82B
Gross Profit	$11.30B
Operating Expenses	$9.07B
Operating Income	$4.05B
Non-Operating Income/Expense	$152.20M
Pre-Tax Income	$4.20B
Normalized Pre-Tax Income	$4.20B
Income after Taxes	$3.95B
Income from Continuous Operations	$3.95B
Consolidated Net Income/Loss	$3.95B
Normalized Income after Taxes	$3.95B
EBIT	$4.05B
EBITDA	$4.47B
Weighted-Average Shares Outstanding (Basic)	106.70M
Weighted-Average Shares Outstanding (Diluted)	113.70M
Earnings per Share (EPS) (Basic)	$37.05
Earnings per Share (EPS) (Diluted)	$34.77
Balance Sheet Financials
Current Assets	$19.48B
Property, Plant, and Equipment	$4.15B
Long-Term Assets	$13.60B
Total Assets	$33.08B
Current Liabilities	$3.42B
Long-Term Debt	$2.70B
Long-Term Liabilities	$3.68B
Total Liabilities	$7.11B
Common Equity	$25.97B
Tangible Shareholders Equity	$24.93B
Shareholders Equity	$25.97B
Common Shares Outstanding	109.40M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$4.59B
Cash Flow from Investing Activities	$-3.19B
Cash Flow from Financial Activities	$-1.79B
Beginning Cash	$3.12B
End Cash	$2.74B
Increase/Decrease in Cash	$-381.60M
Stock-Based Compensation	$885.00M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.69
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.09
Debt to Equity Ratio	0.10
Gross Margin	86.16%
Operating Margin	30.85%
EBIT Margin	30.85%
EBITDA Margin	34.06%
Pre-Tax Profit Margin	32.01%
Profit Margin	30.14%
Free Cash Flow	$3.88B
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.40
Inventory Turnover	0.70
Receiveable Turnover	2.31
Days Sales in Receivables	157.70
Return on Equity	15.22%
Return on Tangible Equity	15.86%
Return on Assets	11.95%
Return on Investments	13.79%
Book Value Per Share	$237.41
Free Cash Flow per Share	$34.08
Operating Cash Flow per Share	$40.40

Data from Zacks Investment Research, Inc.